Quote | Compugen Ltd. (NASDAQ:CGEN)
|Last Trade Date Time:||12/04/2023 03:00:00 am|
News | Compugen Ltd. (NASDAQ:CGEN)
2023-11-07 14:29:07 ET Compugen Ltd. (CGEN) Q3 2023 Earnings Conference Call November 7, 2023 8:30 AM ET Company Participants Yvonne Naughton – Head-Investor Relations and Corporate Communications Anat Cohen-Dayag – President and Chief Executive Officer...
2023-11-07 07:06:52 ET More on Compugen Seeking Alpha’s Quant Rating on Compugen Historical earnings data for Compugen Financial information for Compugen For further details see: Compugen GAAP EPS of -$0.11 misses by $0.02
Message Board Posts | Compugen Ltd. (NASDAQ:CGEN)
|whytestocks: $CGEN News Article - Compugen Doses First Patient in Triple Combination COM701, COM902||whytestocks||investorshangout||03/06/2023 3:55:49 PM|
|whytestocks: $CGEN News Article - Why Compugen Shares Are Up Today||whytestocks||investorshangout||02/28/2023 5:30:50 PM|
|whytestocks: $CGEN News Article - Compugen Reports Fourth Quarter and Full Year 2022 Results||whytestocks||investorshangout||02/27/2023 8:20:49 PM|
|whytestocks: $CGEN News Article - 4 Cheap Penny Stocks To Buy For Under $1 Right Now||whytestocks||investorshangout||11/17/2022 7:45:51 PM|
|whytestocks: $CGEN News Article - Compugen to Receive Milestone Payment Triggered by AstraZeneca's P||whytestocks||investorshangout||11/16/2022 3:15:49 PM|
News, Short Squeeze, Breakout and More Instantly...
Compugen Ltd. Company Name:
CGEN Stock Symbol:
Compugen Reports Third Quarter 2023 Results PR Newswire Rilvegostomig, AstraZeneca's (LSE/STO/Nasdaq: AZN) PD-1/TIGIT bi-specific derived from Compugen's COM902, has progressed into Phase 3 as adjuvant therapy for biliary tract cancer after resection in combination with chemot...
Weyco Group Inc. (WEYS) is expected to report for Q1 2024 Gladstone Land Corporation (LAND) is expected to report $0.16 for Q3 2023 PlayAGS Inc. (AGS) is expected to report $0.01 for Q3 2023 Ardmore Shipping Corporation (ASC) is expected to report $0.43 for Q3 2023 Sage Therapeuti...
Compugen Ltd. (CGEN) is expected to report $-0.09 for Q3 2023